Cancer patients with higher frequencies of PD-1highCD8+TILs showed a worse disease-free survival and OS, a higher simultaneous expression of multiple IMs in CD8+TILs, and a more susceptible response to combined immune therapies [6, 23, 24]. Here, CD8A is linked to cancer.